indomethacin has been researched along with Cachexia in 30 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report that both indomethacin and ibuprofen improved body weight and weight of the gastrocnemius muscle in tumor-bearing mice." | 7.72 | Indomethacin and ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma. ( Al-Majid, S; Hitt, A; McCarthy, DO; Whitney, P, 2004) |
| "Indomethacin-treated tumor-bearing mice were also less anorectic than untreated tumor-bearing mice, and their nutritional state, particularly lean body mass, was significantly improved by indomethacin at doses (1 micrograms/g) that did not influence the food intake or body composition in non-tumor-bearing mice." | 5.28 | Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. ( Andersson, C; Gelin, J; Lundholm, K, 1991) |
| "Unselected cancer patients (n = 108) who experienced progressive cachexia were randomized to receive either anti-inflammatory treatment alone (indomethacin) or recombinant erythropoietin plus indomethacin to prevent the appearance of disease-induced anemia and thereby protect patients' exercise capacity." | 5.11 | Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients. ( Daneryd, P; Fouladiun, M; Hyltander, A; Körner, U; Lindholm, E; Lundholm, K, 2004) |
| " One hundred eight cancer patients who experienced progressive cachexia due to solid, mainly gastrointestinal tumors were randomized to receive twice daily a cyclo-oxygenase inhibitor (controls; indomethacin, 50 mg twice a day) or indomethacin and erythropoietin, provided on individual basis to prevent development of progressive anemia (study patients; indomethacin, 50 mg twice a day plus rhEPO; range, 12,000-30,000 units per week)." | 5.08 | Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study. ( Bosaeus, I; Brevinge, H; Daneryd, P; Körner, U; Lindholm, E; Lundholm, K; Pettersson, C; Sandström, R; Svanberg, E, 1998) |
| " We report that indomethacin, a nonspecific inhibitor of COX, and NS398, a specific inhibitor of COX2, preserved muscle mass and reduced type 1 TNF receptors in muscles of mice bearing the Lewis lung carcinoma, but not in mice bearing the B16 melanoma." | 3.73 | Inhibitors of COX activity preserve muscle mass in mice bearing the Lewis lung carcinoma, but not the B16 melanoma. ( Graves, E; McCarthy, DO; Ramsay, E, 2006) |
| "To assess the putative involvement of NF-kappaB and pro-inflammatory cytokines in the pathogenesis of cancer cachexia and the therapeutic efficacy of indomethacin (IND) on cachexia." | 3.72 | Role of NF-kappaB and cytokine in experimental cancer cachexia. ( Jiang, J; Jiang, ZW; Li, JS; Li, N; Tian, J; Zhou, W, 2003) |
| " We report that both indomethacin and ibuprofen improved body weight and weight of the gastrocnemius muscle in tumor-bearing mice." | 3.72 | Indomethacin and ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma. ( Al-Majid, S; Hitt, A; McCarthy, DO; Whitney, P, 2004) |
| "To assess the putative involvement of NF-kappaB and pro-inflammatory cytokines in the pathogenesis of cancer cachexia and the therapeutic efficacy of indomethacin (IND) on cachexia." | 3.72 | [Role of NF-kappa B in cancer cachexia]. ( Jiang, J; Jiang, ZW; Li, JS; Li, N; Zhou, W, 2004) |
| "To investigate the relationship between cytokine IL-6, IL-1, TNF-alpha and experimental cancer cachexia as well as observe the effect of indomethacin on the cachectic mice." | 3.71 | [Cytokines in experimental cancer cachexia]. ( Li, T; Liu, A; Niu, Q, 2001) |
| " Therefore, the purpose of the present study was to determine if administration of ibuprofen (ibu) or indomethacin (indo), which inhibit PG synthesis, would affect the food intake and body weight of tumor-bearing rats." | 3.70 | Inhibitors of prostaglandin synthesis do not improve food intake or body weight of tumor-bearing rats. ( McCarthy, DO, 1999) |
| "Cancer cachexia is a devastating syndrome of advanced malignancy which negatively impacts on patients' morbidity, mortality and quality of life." | 2.49 | Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review. ( Cantwell, MM; Hughes, CM; Murray, LJ; Parsons, C; Reid, J, 2013) |
| "Pain and cachexia are two of the most debilitating aspects of rheumatoid arthritis." | 1.33 | Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. ( Ho, WH; Pons, J; Rosenthal, A; Shelton, DL; Zeller, J, 2005) |
| "Weight-losing untreated cancer patients had elevated resting energy expenditure compared to undernourished non-cancer patients (23." | 1.32 | Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. ( Bosaeus, I; Daneryd, P; Hyltander, A; Körner, U; Lundholm, K, 2004) |
| "Indomethacin was provided in the drinking water to explore interactions between host and tumor-derived prostaglandins and proinflammatory cytokines for tumor growth." | 1.31 | Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. ( Axelsson, H; Cahlin, C; Körner, A; Lundholm, K; Svanberg, E; Wang, W, 2000) |
| "Local inflammation was induced by subcutaneous injection of turpentine (100 microl/mouse)." | 1.30 | Dietary n-3 fatty acids differentially affect sickness behavior in mice during local and systemic inflammation. ( Conn, CA; Kluger, MJ; Kozak, W; Rudolph, K; Soszynski, D, 1997) |
| "Indomethacin treatment did not affect either of the two CPT activities of the mitochondria isolated from tumour tissue." | 1.30 | Carnitine palmitoyltransferase II activity is decreased in liver mitochondria of cachectic rats bearing the Walker 256 carcinosarcoma: effect of indomethacin treatment. ( Colquhoun, A; Curi, R; Seelaender, MC; Williams, JF; Zammitt, VA, 1998) |
| "A new model of cachexia is described in which muscle protein metabolism related to the ubiquitin-proteasome pathway was investigated." | 1.30 | A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway. ( Brand, SJ; Coggins, MB; Destree, AT; Dick, LR; Elliott, PJ; Goldberg, AL; Huang, JQ; Lazarus, DD; Mazzola, LM; McCormack, TA; Pierce, JW; Read, MA; Solomon, V; Xu, B, 1999) |
| "Indomethacin-treated tumor-bearing mice were also less anorectic than untreated tumor-bearing mice, and their nutritional state, particularly lean body mass, was significantly improved by indomethacin at doses (1 micrograms/g) that did not influence the food intake or body composition in non-tumor-bearing mice." | 1.28 | Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. ( Andersson, C; Gelin, J; Lundholm, K, 1991) |
| "The ability of 13 of the cancer samples to induce muscle proteolysis was significantly inhibited by incubation of muscles in presence of indomethacin (10 microM)." | 1.28 | Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss. ( Belizario, JE; Chenker, E; Katz, M; Raw, I, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.33) | 18.7374 |
| 1990's | 9 (30.00) | 18.2507 |
| 2000's | 17 (56.67) | 29.6817 |
| 2010's | 3 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, B | 1 |
| Li, YX | 1 |
| Pan, HR | 1 |
| Chen, SZ | 1 |
| Qiu, ZG | 1 |
| Reid, J | 1 |
| Hughes, CM | 1 |
| Murray, LJ | 1 |
| Parsons, C | 1 |
| Cantwell, MM | 1 |
| Zhou, W | 2 |
| Jiang, ZW | 2 |
| Tian, J | 1 |
| Jiang, J | 2 |
| Li, N | 2 |
| Li, JS | 2 |
| Lundholm, K | 7 |
| Daneryd, P | 4 |
| Körner, U | 3 |
| Hyltander, A | 2 |
| Bosaeus, I | 2 |
| McCarthy, DO | 4 |
| Whitney, P | 1 |
| Hitt, A | 2 |
| Al-Majid, S | 1 |
| Lindholm, E | 2 |
| Fouladiun, M | 1 |
| Graves, E | 2 |
| Wang, W | 2 |
| Andersson, M | 1 |
| Lõnnroth, C | 2 |
| Svanberg, E | 3 |
| Shelton, DL | 1 |
| Zeller, J | 1 |
| Ho, WH | 1 |
| Pons, J | 1 |
| Rosenthal, A | 1 |
| Ramsay, E | 1 |
| Diament, MJ | 1 |
| Peluffo, GD | 1 |
| Stillitani, I | 1 |
| Cerchietti, LC | 1 |
| Navigante, A | 1 |
| Ranuncolo, SM | 1 |
| Klein, SM | 1 |
| Granado, M | 1 |
| Martín, AI | 1 |
| Villanúa, MA | 1 |
| López-Calderón, A | 1 |
| de Sá-Nakanishi, AB | 1 |
| Bracht, F | 1 |
| Yamamoto, NS | 1 |
| Padilha, F | 1 |
| Kelmer-Bracht, AM | 1 |
| Bracht, A | 1 |
| Smith, KL | 1 |
| Tisdale, MJ | 1 |
| Roe, SY | 1 |
| Cooper, AL | 1 |
| Morris, ID | 1 |
| Rothwell, NJ | 1 |
| Kozak, W | 1 |
| Soszynski, D | 1 |
| Rudolph, K | 1 |
| Conn, CA | 1 |
| Kluger, MJ | 1 |
| Seelaender, MC | 1 |
| Curi, R | 2 |
| Colquhoun, A | 1 |
| Williams, JF | 1 |
| Zammitt, VA | 1 |
| Sandström, R | 1 |
| Brevinge, H | 1 |
| Pettersson, C | 1 |
| Lazarus, DD | 1 |
| Destree, AT | 1 |
| Mazzola, LM | 1 |
| McCormack, TA | 1 |
| Dick, LR | 1 |
| Xu, B | 1 |
| Huang, JQ | 1 |
| Pierce, JW | 1 |
| Read, MA | 1 |
| Coggins, MB | 1 |
| Solomon, V | 1 |
| Goldberg, AL | 1 |
| Brand, SJ | 1 |
| Elliott, PJ | 1 |
| Cahlin, C | 2 |
| Gelin, J | 2 |
| Delbro, D | 1 |
| Doi, C | 1 |
| Körner, A | 1 |
| Axelsson, H | 1 |
| Eli, Y | 1 |
| Przedecki, F | 1 |
| Levin, G | 1 |
| Kariv, N | 1 |
| Raz, A | 1 |
| Niu, Q | 1 |
| Li, T | 1 |
| Liu, A | 1 |
| Andersson, C | 1 |
| Belizario, JE | 1 |
| Katz, M | 1 |
| Chenker, E | 1 |
| Raw, I | 1 |
| Homem-de-Bittencourt Júnior, PI | 1 |
| Pontieri, V | 1 |
| Lopes, OU | 1 |
1 review available for indomethacin and Cachexia
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cachexia; Celecoxib; Cyclooxygenase 2 I | 2013 |
3 trials available for indomethacin and Cachexia
| Article | Year |
|---|---|
Effects of recombinant erythropoietin in palliative treatment of unselected cancer patients.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Cachexia; Drug Therapy, Combination; | 2004 |
Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: a randomized prospective study.
Topics: Aged; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Cachexia; Cyclooxygenase Inhibitors; Energy M | 1998 |
Epoetin alfa for protection of metabolic and exercise capacity in cancer patients.
Topics: Aged; Anemia; Anti-Inflammatory Agents, Non-Steroidal; Cachexia; Cyclooxygenase Inhibitors; Energy M | 2002 |
26 other studies available for indomethacin and Cachexia
| Article | Year |
|---|---|
[Study on Regulation Effects of Yiqiyangyin Formula on Advanced Lung Cancer Cachexia Mice].
Topics: Animals; Cachexia; Cytokines; Indomethacin; Lung; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL | 2016 |
Combined treatment with GH, insulin, and indomethacin alleviates cancer cachexia in a mouse model.
Topics: Adenocarcinoma; Animals; Biomarkers; Body Weight; Cachexia; Colonic Neoplasms; Cytokines; Drug Combi | 2011 |
Role of NF-kappaB and cytokine in experimental cancer cachexia.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Composition; Cachexia; Coloni | 2003 |
Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Blood Sedim | 2004 |
Indomethacin and ibuprofen preserve gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cachexia; Colonic Neo | 2004 |
[Role of NF-kappa B in cancer cachexia].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cachexia; Colonic Neoplasms; Indom | 2004 |
Indomethacin preserves muscle mass and reduces levels of E3 ligases and TNF receptor type 1 in the gastrocnemius muscle of tumor-bearing mice.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, We | 2005 |
Prostaglandin E and prostacyclin receptor expression in tumor and host tissues from MCG 101-bearing mice: a model with prostanoid-related cachexia.
Topics: Animals; Base Sequence; Body Weight; Cachexia; Dinoprostone; Disease Models, Animal; DNA Primers; DN | 2005 |
Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis, Experimental; C | 2005 |
Inhibitors of COX activity preserve muscle mass in mice bearing the Lewis lung carcinoma, but not the B16 melanoma.
Topics: Analysis of Variance; Animals; Cachexia; Carcinoma, Lewis Lung; Cyclooxygenase Inhibitors; Female; I | 2006 |
Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; A | 2006 |
Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation.
Topics: Animals; Arthritis, Experimental; Cachexia; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhi | 2007 |
The action of extracellular NAD+ in the liver of healthy and tumor-bearing rats: model analysis of the tumor-induced modified response.
Topics: Animals; Cachexia; Carcinoma 256, Walker; Eicosanoids; Extracellular Fluid; Glucose; Hemodynamics; I | 2008 |
Mechanism of muscle protein degradation in cancer cachexia.
Topics: Adenocarcinoma; Animals; Cachexia; Dinoprostone; Eicosapentaenoic Acid; Female; Indomethacin; Mice; | 1993 |
Involvement of prostaglandins in cachexia induced by T-cell leukemia in the rat.
Topics: Animals; Body Temperature Regulation; Body Weight; Cachexia; Feeding Behavior; Flurbiprofen; Indomet | 1997 |
Dietary n-3 fatty acids differentially affect sickness behavior in mice during local and systemic inflammation.
Topics: Animals; Anorexia; Behavior, Animal; Body Temperature; Body Weight; Cachexia; Coconut Oil; Fatty Aci | 1997 |
Carnitine palmitoyltransferase II activity is decreased in liver mitochondria of cachectic rats bearing the Walker 256 carcinosarcoma: effect of indomethacin treatment.
Topics: Animals; Cachexia; Carcinoma 256, Walker; Carnitine O-Palmitoyltransferase; Cell Division; Dinoprost | 1998 |
A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.
Topics: Animals; Cachexia; Cysteine Endopeptidases; Dexamethasone; Disease Models, Animal; Glucocorticoids; | 1999 |
Inhibitors of prostaglandin synthesis do not improve food intake or body weight of tumor-bearing rats.
Topics: Analysis of Variance; Animals; Anorexia; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cache | 1999 |
Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids.
Topics: Animals; Cachexia; Dinoprostone; Disease Models, Animal; Enzyme Inhibitors; Female; Gene Expression | 2000 |
Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Body Weight; Cachexia; Cell Division; | 2000 |
Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apopt | 2001 |
[Cytokines in experimental cancer cachexia].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Body Weight; Cachex | 2001 |
Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia.
Topics: Animals; Body Weight; Cachexia; Cyclosporins; Eating; Female; Indomethacin; Interleukin-1; Interleuk | 1991 |
Bioactivity of skeletal muscle proteolysis-inducing factors in the plasma proteins from cancer patients with weight loss.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Blood Proteins; Cachexia; Child; Diaphragm; Fem | 1991 |
Effects of aspirin-like drugs on Walker 256 tumor growth and cachexia in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; Cachexia; Carcinoma 256, Wal | 1989 |